CEMI - Chembio Diagnostics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
5.80
-0.08 (-1.36%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close5.88
Open5.89
Bid5.66 x 1400
Ask12.35 x 1800
Day's Range5.65 - 5.92
52 Week Range4.85 - 11.55
Volume31,526
Avg. Volume35,014
Market Cap99.566M
Beta (3Y Monthly)1.59
PE Ratio (TTM)N/A
EPS (TTM)-0.65
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.25
Trade prices are not sourced from all markets
  • Should You Be Concerned About Chembio Diagnostics, Inc.'s (NASDAQ:CEMI) Historical Volatility?
    Simply Wall St.2 days ago

    Should You Be Concerned About Chembio Diagnostics, Inc.'s (NASDAQ:CEMI) Historical Volatility?

    Anyone researching Chembio Diagnostics, Inc. (NASDAQ:CEMI) might want to consider the historical volatility of the...

  • GlobeNewswire20 days ago

    Chembio Diagnostics Receives CE Mark for its Point-of-Care Multiplex Test for Zika, Dengue and Chikungunya

    Chembio Diagnostics, Inc. (CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced that is has obtained a CE mark for its DPP Zika/Dengue/Chikungunya multiplex test system. Chembio’s DPP Zika/Dengue/Chikungunya multiplex test allows simultaneous and discrete detection of antibodies for both active (IgM) and prior exposure (IgG) to the Zika, dengue, and chikungunya viruses, which is important for both treatment and surveillance. The test is performed using a small (10µL) drop of fingertip blood and provides quantitative results in approximately 15 minutes when used with the company’s handheld DPP Micro Reader.

  • GlobeNewswire2 months ago

    Chembio Diagnostics Announces Approval of Dengue Point-of-Care Test by Brazil’s Health Regulatory Agency

    Chembio Diagnostics, Inc. (CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced the approval of its DPP Dengue System by Agência Nacional de Vigilância Sanitária (ANVISA), Brazil’s health regulatory agency, in collaboration with Bio-Manguinhos, a Brazilian government agency and supplier of diagnostic products to Brazil’s Ministry of Health. Chembio’s DPP Dengue test allows simultaneous and discrete detection of antibodies against all four dengue serotypes for both active infection by dengue virus (IgM) and prior exposure to the dengue virus (IgG), which is important for both treatment and surveillance.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of CEMI earnings conference call or presentation 1-May-19 8:30pm GMT

    Q1 2019 Chembio Diagnostics Inc Earnings Call

  • GlobeNewswire3 months ago

    Chembio Diagnostics Reports First Quarter 2019 Financial Results

    MEDFORD, N.Y., May 01, 2019 -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial.

  • Introducing Chembio Diagnostics (NASDAQ:CEMI), The Stock That Zoomed 142% In The Last Five Years
    Simply Wall St.3 months ago

    Introducing Chembio Diagnostics (NASDAQ:CEMI), The Stock That Zoomed 142% In The Last Five Years

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! The worst result, after buying shares in a company (assuming no leverage), would be if you lose all...

  • GlobeNewswire3 months ago

    Chembio Diagnostics to Report First Quarter 2019 Financial Results on May 1, 2019

    Chembio Diagnostics, Inc. (CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will release financial results for the first quarter of 2019 after the close of trading on Wednesday, May 1, 2019. Chembio is a leading point-of-care diagnostics company focused on detecting and diagnosing infectious diseases. The company’s patented DPP technology platform, which uses a small drop of blood from the fingertip, provides high-quality, cost-effective results in approximately 15 minutes.

  • GlobeNewswire3 months ago

    Chembio Diagnostics Announces Approval of Zika, Dengue and Chikungunya Point-of-Care Multiplex Test by Brazil’s Health Regulatory Agency

    Chembio Diagnostics, Inc. (CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced the approval of its DPP Zika/Dengue/Chikungunya System by Agência Nacional de Vigilância Sanitária (ANVISA), Brazil’s health regulatory agency, in collaboration with Bio-Manguinhos/Fiocruz. Chembio’s DPP Zika/Dengue/Chikungunya multiplex test allows simultaneous and discrete detection of antibodies for both active (IgM) and prior exposure (IgG) to the Zika, dengue, and chikungunya viruses, which is important for both treatment and surveillance. The test is performed using a small (10µL) drop of fingertip blood and provides quantitative results in approximately 15 minutes when used with the company’s handheld DPP Micro Reader.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of CEMI earnings conference call or presentation 7-Mar-19 9:30pm GMT

    Q4 2018 Chembio Diagnostics Inc Earnings Call

  • GlobeNewswire3 months ago

    Chembio Diagnostics Announces Agreement with Perseus Science to Advance Point-of-Care Concussion Test

    Chembio Diagnostics, Inc. (CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced that the company has entered into an agreement with Perseus Science Group LLC, to advance the development of a diagnostic test for mild traumatic brain injury (TBI), or concussion. This agreement builds on previous agreements between the two firms that resulted in the completion of technical feasibility to detect Perseus’ patented biomarker. Under terms of this agreement, Chembio will receive funding from Perseus, subject to satisfying certain milestones, to advance the development of a quantitative point-of-care test for concussion, combining Chembio's proprietary DPP platform with Perseus’ biomarker.

  • Zacks Small Cap Research4 months ago

    CEMI: Revenue, margin guidance and historical context indicates this could be opportune entry point

    Chembio (CEMI) reported financial results for their fourth quarter ending December 31st and provided an operating update. Product sales were just about dead-on with our estimate and up 16% yoy to $5.6M. Total revenue jumped 27% to $7.6M, aided by a very healthy $1.7M in R&D contracts, milestones and grant revenue – which is the greatest quarterly revenue from this category in company history.

  • GuruFocus.com4 months ago

    Chembio Diagnostics Inc (CEMI) Files 10-K for the Fiscal Year Ended on December 31, 2018

    Chembio Diagnostics Inc develops, manufactures, and commercializes point of care diagnostic tests that detect infectious diseases. Warning! GuruFocus has detected 4 Warning Signs with CEMI. For the last quarter Chembio Diagnostics Inc reported a revenue of $7.60 million, compared with the revenue of $5.99 million during the same period a year ago.

  • Have Insiders Been Buying Chembio Diagnostics, Inc. (NASDAQ:CEMI) Shares?
    Simply Wall St.4 months ago

    Have Insiders Been Buying Chembio Diagnostics, Inc. (NASDAQ:CEMI) Shares?

    We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be remiss not to mention that insider sales haveRead More...

  • GlobeNewswire4 months ago

    Chembio Diagnostics Reports Fourth Quarter and Full Year 2018 Financial Results

    MEDFORD, N.Y., March 07, 2019 -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial.

  • GlobeNewswire4 months ago

    Chembio Diagnostics Awarded UNICEF Contract to Supply Point-of-Care Zika/Chikungunya/Dengue Tests and Micro Readers

    Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leader in point-of-care diagnostic tests for infectious diseases, today announced that it will be awarded a conditional Long Term Arrangement (LTA) from UNICEF for purchases of the company’s DPP® Zika/Chikungunya/Dengue System. The UNICEF LTA, which is valid through December 31, 2020, includes a firm purchase commitment of $1.5 million and possible additional purchases of up to $2.0 million, for a total amount of up to $3.5 million. All of the purchases are subject to Chembio meeting the following conditions: receipt of CE mark certification, completion of clinical and analytical performance evaluation, and a successful quality management system (QMS) inspection.

  • GlobeNewswire5 months ago

    Chembio Diagnostics to Report Fourth Quarter and Full Year 2018 Financial Results on March 7, 2019

    Chembio Diagnostics, Inc. (CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will release financial results for the fourth quarter and full year 2018 after the close of trading on Thursday, March 7, 2019. Chembio Diagnostics, Inc. is a leading point-of-care diagnostics company focused on detecting and diagnosing infectious diseases. The Company’s patented DPP technology platform, which uses a small drop of blood from the fingertip, provides high-quality, cost-effective results in approximately 15 minutes.

  • GlobeNewswire5 months ago

    Chembio Diagnostics to Participate in the BTIG Medical Technology, Life Science and Diagnostic Tools Conference

    MEDFORD, N.Y., Feb. 19, 2019 -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today the.

  • Do Insiders Own Shares In Chembio Diagnostics, Inc. (NASDAQ:CEMI)?
    Simply Wall St.5 months ago

    Do Insiders Own Shares In Chembio Diagnostics, Inc. (NASDAQ:CEMI)?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! If you want to know who reallyRead More...

  • GlobeNewswire5 months ago

    Chembio Diagnostics Reports Preliminary Fourth Quarter and Full Year 2018 Revenue

    Chembio Diagnostics, Inc. (CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today preliminary estimates of revenue for the fourth quarter and full year 2018, as well as long-term strategic targets. Revenue for the fourth quarter of 2018 is expected to be between $7.3 million and $7.6 million, an increase of approximately 22% to 27% compared to the fourth quarter of 2017. As a result, there is a possibility that final revenue results will not be within the ranges Chembio currently estimates.  The company undertakes no responsibility to update its revenue outlook.

  • GlobeNewswire6 months ago

    Chembio Diagnostics Announces 2019 Analyst and Investor Meeting

    MEDFORD, N.Y., Jan. 17, 2019 -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it.

  • GlobeNewswire6 months ago

    Chembio Diagnostics Receives CE Mark for Point-of-Care Diagnostic Test  Developed in Collaboration with AstraZeneca

    MEDFORD, N.Y., Jan. 07, 2019 -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced that it.

  • Chembio Diagnostics, Inc.’s (NASDAQ:CEMI) Path To Profitability
    Simply Wall St.6 months ago

    Chembio Diagnostics, Inc.’s (NASDAQ:CEMI) Path To Profitability

    Chembio Diagnostics, Inc.'s (NASDAQ:CEMI): Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or monitor diseases. With the latest Read More...

  • GlobeNewswire7 months ago

    Chembio’s French Partner AAZ-LMB Wins Prix Galien International for Best Medical Technology with autotest VIH®

    MEDFORD, N.Y., Dec. 06, 2018 -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced that its.

  • Zacks Small Cap Research8 months ago

    CEMI: Record YTD Revenue, Margin Improvement Should Soon Follow

    Chembio (CEMI) reported financial results for their third quarter ending September 30, 2018. Q3 made it three-for-three with us substantially underestimating product and total revenue every quarter so far in 2018. While it is unclear exactly what is catalyzing product revenue or where we’re missing, recently secured contracts (such as that with Bio-Manghinos) and international tenders (including the $15.8M tender from Ethiopia) are undoubtedly significant contributors to the record YTD revenue.

  • Thomson Reuters StreetEvents8 months ago

    Edited Transcript of CEMI earnings conference call or presentation 8-Nov-18 9:30pm GMT

    Q3 2018 Chembio Diagnostics Inc Earnings Call